Gregory A Yanik
Datos Biográficos
| ID | 8306499 |
|---|---|
| NOMBRE | Gregory A Yanik |
| NOMBRES | Gregory A |
| APELLIDO | Yanik |
| FIRMA | YANIK G A |
| AFILIACIONES | University of Michigan |
| ORCID | 0000-0003-3829-4940 |
| VERIFICADO | Sí |
| TOTAL DE OBRAS | 1 |
| TOTAL DE CITAS | 0 |
| OBRAS COMO AUTOR | 1 |
| OBRAS COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2019 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2019 |
| ÍNDICE H | 0 |
How Should We Determine the Value of CAR T-Cell Therapy
In 2017, the US Food and Drug Administration approved the first chimeric antigen receptor (CAR) T-cell therapies for patients with relapsed or refractory B-cell leukemia and selected B-cell lymphomas. This novel form of cellular immunotherapy creates a "living drug" that effectively reprograms a patient's T cells to target specific antigens on the surface of a tumor. The therapy has high response rates in patients with refractory disease, althoug…
Sin obras prominentes en esta página.
How Should We Determine the Value of CAR T-Cell Therapy
In 2017, the US Food and Drug Administration approved the first chimeric antigen receptor (CAR) T-cell therapies for patients with relapsed or refractory B-cell leukemia and selected B-cell lymphomas. This novel form of cellular immunotherapy creates a "living drug" that effectively reprograms a patient's T cells to target specific antigens on the surface of a tumor. The therapy has high response rates in patients with refractory disease, althoug…
Antigen (1 obra) · Biology (1 obra) · Biomedical Ethics and Regulation (1 obra) · Cancer Research (1 obra) · CAR-T cell therapy research (1 obra) · Cell (1 obra) · Cell therapy (1 obra) · Chimeric antigen receptor (1 obra) · Disease (1 obra) · Drug (1 obra)